Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Positron Emission Tomography (PET) Nuclear Medicine Market Over The Five-Year Period 2025–2029?
The positron emission tomography (pet) nuclear medicine market has experienced substantial expansion in recent years. Projections indicate it will grow from $11.49 billion in 2024 to $13.16 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.5%. The market’s past growth is attributable to the increasing prevalence of cardiovascular diseases, rising healthcare expenditures, a greater incidence of urological diseases, the expanding geriatric population, and an increase in the number of hospitals.
The positron emission tomography (pet) nuclear medicine market is anticipated to experience substantial expansion in the coming years. This market is projected to attain a size of $22.52 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.4%. The expansion foreseen for this period is largely driven by increased investments in research and development, a growing preference for minimally invasive diagnostic techniques, the ongoing development of global healthcare infrastructure, a heightened need for food and pharmaceutical packaging, and the rising prevalence of cancer. Significant developments anticipated during the forecast period include technological advancements, the practice of multi-modality diagnosis, the integration of artificial intelligence, the advent of digital PET systems, and the progression of personalized medicine.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19151&type=smp
What Are The Key Drivers Of Growth In The Positron Emission Tomography (PET) Nuclear Medicine Market?
The anticipated expansion of the positron emission tomography (PET) nuclear medicine market is linked to the rising occurrence of chronic illnesses. Such a disease is defined as a persistent health state, usually lasting at least three months, often necessitating continuous medical care or restricting daily functions. Key contributors to the increase in chronic conditions include an aging demographic, insufficient physical exercise, poor dietary practices, and exposure to environmental hazards. PET nuclear medicine plays a crucial role in managing these long-term conditions by providing sophisticated imaging techniques that facilitate early identification, accurate diagnostic assessments, and continuous oversight of the diseases. For example, data from February 2024, sourced from the World Health Organization (WHO), a Switzerland-based intergovernmental body, indicated approximately 20 million new cancer cases and 9.7 million cancer-related deaths were registered in 2022. Furthermore, projections suggest that by 2050, the number of new cancer cases will surpass 35 million, marking a 77% surge compared to the 2022 figures. Consequently, the rising incidence of chronic ailments is a primary catalyst for the expansion of the positron emission tomography (PET) nuclear medicine market.
How Is The Positron Emission Tomography (PET) Nuclear Medicine Market Segmented?
The positron emission tomography (pet) nuclear medicinemarket covered in this report is segmented –
1) By Type: F-18; Rb-82; Other Types
2) By Procedure: Diagnostic Procedures; Single Photon Emission Computed Tomography Procedures; Positron Emission Tomography Procedures; Therapeutic Procedures; Beta Emitter Procedures; Alpha Emitter Procedures; Brachytherapy Procedures
3) By Application: Oncology; Cardiology; Neurology; Other Applications
4) By End User: Hospitals; Diagnostic Centers; Research Institutes
Subsegments:
1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose); F-18 NaF (Sodium Fluoride); F-18 Fluorocholine
2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging; Rb-82 for Cardiac PET Stress Testing; Rb-82 for Other Cardiac Applications
3) By Other Types: C-11 (Carbon-11); N-13 (Nitrogen-13); O-15 (Oxygen-15); Ga-68 (Gallium-68)
What Key Innovation Trends Are Fueling Advancements In The Positron Emission Tomography (PET) Nuclear Medicine Market?
Major companies operating in the positron emission tomography (PET) nuclear medicine market are developing technologically advanced products, such as PET slice scanners, to provide high-resolution images of metabolic activity. A PET slice scanner is a medical imaging device that integrates positron emission tomography (PET) with advanced computing techniques to produce detailed, cross-sectional images of metabolic processes within the body, facilitating the detection and monitoring of diseases, especially cancer. For instance, in July 2024, Positron Corporation, a US-based nuclear medicine company, launched its NeuSight PET-CT 3D 64-slice scanner. This NeuSight PET-CT 3D 64-slice scanner sets a new benchmark in imaging and diagnostic precision by combining advanced technology with enhanced patient comfort and operational efficiency. It is designed to transform cardiac PET imaging, offering exceptional value and performance at an unmatched price point, which makes it ideal for cardiology and oncology clinical studies. With its superior data acquisition and innovative identification technology, the NeuSight PET-CT boosts scanning speed and accuracy, delivering comprehensive anatomic and functional imaging for heart, tumor, and brain studies across various molecular imaging applications.
Which Leading Companies Dominate The Positron Emission Tomography (PET) Nuclear Medicine Market Share?
Major companies operating in the positron emission tomography (PET) nuclear medicine marker are Cardinal Health, Bayer AG, Medtronic plc, Siemens Healthineers AG, Fujifilm Holdings Corporation, Stryker Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Agfa HealthCare NV, Scripps Health, Shimadzu Corporation, Jubilant DraxImage Inc., Neusoft Medical Systems Co. Ltd., Toshiba America Medical Systems Inc., Lantheus Holdings Inc., Advanced Accelerator Applications, Bruker Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, Canon Medical Systems Corporation, Digirad Corporation, NorthStar Medical Radioisotopes LLC, Mediso Medical Imaging Systems Ltd.
Download The Full Report For Exclusive Market Findings:
Which Region Is Projected To Lead The Positron Emission Tomography (PET) Nuclear Medicine Market During The Forecast Period?
North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) nuclear medicine marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Positron Emission Tomography (PET) Nuclear Medicine Market Report:
https://www.thebusinessresearchcompany.com/customise?id=19151&type=smp
Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Nuclear Medicine Market 2025, By The Business Research Company
Positron Emission Tomography Pet Scanners Global Market Report 2025
Single Photon Emission Computed Tomography Spect Global Market Report 2025
Nuclear Medicine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model